Transaction · 0001737329-26-000016

Iannone Robert

Iannone Robert, EVP, GHR, D, CMO, reported an open-market or private sale at Jazz Pharmaceuticals plc involving 9259.000000 shares for an estimated $2332804.12. Reported holdings after the transaction were 65986.000000 shares. The stored filing text includes a detected 10b5-1 reference.

Open-market sellSEC transaction code SEVP, GHR, D, CMO
JAZZJazz Pharmaceuticals plc
Trade date
Aug 27, 2026
Filing date
Aug 31, 2026
View on SEC Insider profile
Estimated value-$2.33MShares × reported price
Shares traded9.25k$251.95 per share
Holdings after65.9kDirect
% of reported position traded12.31%This security and ownership context
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 75,245 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

JAZZ price since this filing

Daily closing prices, with the filing date and available return windows
JAZZ · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +2.5%1w ago -0.8%1d ago -0.6%
Returns since7d -1.5%30d -7.6%90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0001737329-26-000016
Ordinary Shares
Transaction date
Aug 27, 2026
Filed Aug 31, 2026, 10:45 PM · 4d delay
Shares
9,259 sh
$251.95 per share
Estimated value
-$2.33M
Computed from shares × price
Holdings after
65,986 sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Direct Ownership Large Sale Repeat Seller 10b5-1 Detected
Filing-only score

-4 points

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

How this score is calculated
  • direct_ownership+6 points

    direct_or_indirect_ownership = D

    Direct ownership reports the insider's personal stake.
  • tenb5_1_detected-10 points

    is_10b5_1 = true

    Stored filing content includes detected 10b5-1 language.
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

EVP, Global Head of R&D & CMO

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    This transaction was made pursuant to a plan adopted by the reporting person on May 28, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred…

  2. F2

    Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $247.29 to $248.24. The price reported reflects the weighted average sale price. The Reporting Person hereby…

  3. F3

    Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $248.29 to $249.24. The price reported reflects the weighted average sale price. The Reporting Person hereby…

  4. F4

    Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $249.33 to $250.325 The price reported reflects the weighted average sale price. The Reporting Person hereby…

  5. F5

    Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $250.33 to $251.29. The price reported reflects the weighted average sale price. The Reporting Person here…

  6. F6

    Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $251.37 to $252.31. The price reported reflects the weighted average sale price. The Reporting Person here…

  7. F7

    These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, February 27, 2020, with 1…

  8. F8

    These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the vesting commencement date of May 29,…

Original filing · 0001737329-26-000016
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

JAZZ